Eisai Anticipates Full Approval of Leqembi as Early as July

After winning accelerated approval in January, Eisai is anticipating full FDA approval for Alzheimer's drug Leqembi (lecanemab) as early as this summer.

With priority review granted in January, full approval could come as soon as July, Ivan Cheung, chairman and CEO, Eisai Inc., told CNBC Thursday.